News & Updates

Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab
Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab
27 Apr 2023 byAudrey Abella

In patients with locally advanced or metastatic urothelial cancer patients receiving atezolizumab treatment, immune-related adverse events (AEs) were associated with improved survival outcomes, according to an analysis of individual participant data from the IMvigor210 and IMvigor211 studies.

Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab
27 Apr 2023